/
OTLK
$0.91-$0.21 (-19.20%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$205.7M
187M shares
52-week range
$0.16 – $3.39
23% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-42.31
Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
www.outlooktherapeutics.com- Employees
- 17
- IPO / List date
- May 13, 2016
- HQ
- ISELIN, NJ
Held by traders on TradeandTell
No one on the platform currently holds OTLK.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 255,157 | $52.5K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-03-14 | 1-for-20reverse |
| 2019-03-18 | 1-for-8reverse |
Recent trades on TradeandTell
No one on the platform has traded OTLK yet.
